McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports
Option Care Health stock skyrocketed following a $5.8 billion buyout agreement with McKesson and CD&R.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Recent reporting outlines a major corporate transaction involving the acquisition of Option Care Health. According to coverage from Bloomberg.com, Reuters, Axios, WSJ, Yahoo Finance, Investor's Business Daily, KSL News, Quiver Quantitative, TradingView, Demócrata, The Motley Fool, and The Business Journals, McKesson and CD&R are joining forces to buy Option Care Health. The deal values the infusion therapy provider at approximately $5.8 billion, or $32.05 per share. Outlets note that the agreement will take the company private. Stock market reactions were immediate, with coverage from The Motley Fool and Quiver Quantitative highlighting that Option Care Health stock skyrocketed on Tuesday following the announcement. Financial publications and news agencies have extensively covered the transaction details.
Reporting from Reuters initially noted that the parties were near a five billion-plus deal before subsequent updates confirmed the $5.8 billion valuation. Demócrata reported the purchase value in different currency terms reflecting European coverage, while TradingView and Investor's Business Daily emphasized McKesson's specific role in taking a stake and striking the multibillion-dollar transaction. The Business Journals also briefly mentioned a separate transaction involving Energy Transfer buying Vaquero for $2.6 billion alongside the broader business news cycle. Context surrounding the acquisition centers on Option Care Health's position as an at-home infusion therapy provider, a detail underscored by WSJ, Reuters, and KSL News. Taking the company private through the combined efforts of CD&R and McKesson marks a significant consolidation within the healthcare and infusion services sector. The available coverage extensively documents the per-share pricing and the total financial scope of the buyout without detailing prior acquisition discussions or historical corporate friction.
Future updates from the cited financial news networks will track the formal closing process of the private buyout. Coverage does not yet specify the exact calendar date when the transaction will officially finalize. Stakeholders will also monitor regulatory reviews and shareholder filings as reported by the outlets tracking the developments. As the corporate transition proceeds, market analysts continue to evaluate the implications for the healthcare sector. Readers should consult ongoing reports from Reuters, Bloomberg.com, and Yahoo Finance for official corporate communications regarding the timeline.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 40d ago.
Quick answers
Who is acquiring Option Care Health?
McKesson and CD&R are acquiring Option Care Health.
What is the valuation of the deal?
The deal is valued at approximately $5.8 billion, with shares priced at $32.05.
What type of business does Option Care Health operate?
Option Care Health operates as an infusion therapy provider.
Coverage (14)
- McKesson part of $5.8 billion buyout; Energy Transfer to buy Vaquero for $2.6 billion The Business Journals · 43d ago
- Why Option Care Health Stock Skyrocketed on Tuesday The Motley Fool · 43d ago
- Option Care Health Agrees to $5.8 Billion Acquisition by CD&R and McKesson at $32.05 Per Share Yahoo Finance · 43d ago
- McKesson, CD&R to Buy Option Care in $5.8 Billion Deal Bloomberg.com · 43d ago
- CD&R and McKesson close the purchase of Option Care Health for 5.150 million Demócrata · 43d ago
- McKesson Takes A Stake In Option Care TradingView · 43d ago
- Option Care Health jumps after $32.05-per-share buyout deal Quiver Quantitative · 43d ago
- McKesson, CD&R to take infusion therapy provider Option Care private in $5.8 billion deal KSL News · 43d ago
- McKesson Strikes A $5.8 Billion Deal; One Stock Skyrockets Investor's Business Daily · 43d ago
- CD&R, McKesson to Acquire At-Home Infusion Therapy Provider for $5.8 Billion WSJ · 43d ago
- McKesson, CD&R to Buy Option Care Health in $5.8 Billion Deal Yahoo Finance · 43d ago
- McKesson, CD&R to take infusion therapy provider Option Care private in $5.8 billion deal Reuters · 43d ago
- McKesson and CD&R to acquire Option Care Health for around $5.8B Axios · 43d ago
- McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports Reuters · 43d ago
Topics
Related trends
Warburg Pincus and CD&R near deal to buy Canaccord’s UK wealth division
Warburg Pincus and CD&R are nearing a deal to acquire Canaccord's UK wealth division.
Top Wall Street analysts recommend these 3 dividend stocks for higher returns
Wall Street analysts are identifying high-yield dividend stocks in the energy sector as oil prices continue to rise.
Exclusive | Texas Stock Exchange Is Close to Winning Its First Major Listing From New York
The Texas Stock Exchange is challenging New York's financial dominance as Energy Transfer and Sunoco prepare to transfer their corporate listings.
McKesson strikes $2.25 billion Precision Medicine deal in clinical research bets
McKesson has entered a definitive agreement to acquire Precision Medicine Group, LLC for $2.25 billion to expand its clinical research capabilities.
Exclusive: Oracle Data Centers Face Multibillion-Dollar Cost Surprises
Oracle's data center expansion faces multibillion-dollar cost surprises and critical regulatory setbacks in New Mexico.
McKesson and CD&R strike $5.8bn deal to buy infusion services provider
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.